KontRASt-02 is a phase III trial evaluating the efficacy of opunarasib vs. docetaxel in advanced NSCLC [NCT05132075], whereas KontRASt-03 is evaluating opunarasib in select combinations with tislelizumab (PD-1 antibody), trametinib (MEK inhibitor), ribociclib (cyclin-dependent kinase 4/6 inhibitor), or cetuximab (EGFR antibody) [NCT05358249]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.